News Room

News Releases

Apr. 23, 2021 (PDF/125KB)Finances

Sumitomo Dainippon Pharma Announces Revisions to Its Financial Forecasts
Apr. 13, 2021 (PDF/81KB)Products

Urovant Sciences Announces U.S. Commercial Launch of GEMTESA (vibegron) 75 mg Tablets for Patients with Overactive Bladder
Apr. 09, 2021 (PDF/113KB)CSR

Sumitomo Dainippon Pharma Receives the "Intellectual Property Achievement Awards" for the First Time
Mar. 31, 2021 (PDF/194KB)R&D

The GHIT Fund Awards Grant for the Development of a New Malaria Pre-erythrocytic Vaccine
Mar. 30, 2021 (PDF/85KB)Corporate

Sumitovant Completes the "Going Private" Transaction with Our Consolidated Subsidiary, Urovant
Mar. 30, 2021 (PDF/38KB)R&D

Myovant Sciences Announces European Medicines Agency Validation of Marketing Authorization Application for Relugolix for the Treatment of Advanced Prostate Cancer
Mar. 29, 2021R&D

Posted Video of Sumitovant Meeting [Webcast]
Mar. 23, 2021 (PDF/6,694KB)R&D

Posted Presentation Material (Sumitovant Meeting)
Mar. 05, 2021 (PDF/97KB)Finances

Sumitomo Dainippon Pharma Announces Posting of Impairment Loss
Mar. 04, 2021 (PDF/125KB)CSR

Sumitomo Dainippon Pharma Earns Recognition for the First Time in the Health & Productivity Management Stock Selection

Nov. 01, 2019 (PDF/1,557KB)Corporate

Press Conference Presentation for Definitive Agreement for Strategic Alliance with Roivant Sciences
Oct. 28, 2019 (PDF/926KB)Finances

Press Conference Presentation for Q2 FY2019 (April 1 to September 30, 2019)
Dec. 02, 2013 (PDF/414KB)R&D

Presentation material of press conference (Healios and DSP: Alliance for Japanese market-iPS cell technology into practical use-)